JP2010522185A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522185A5
JP2010522185A5 JP2009554635A JP2009554635A JP2010522185A5 JP 2010522185 A5 JP2010522185 A5 JP 2010522185A5 JP 2009554635 A JP2009554635 A JP 2009554635A JP 2009554635 A JP2009554635 A JP 2009554635A JP 2010522185 A5 JP2010522185 A5 JP 2010522185A5
Authority
JP
Japan
Prior art keywords
myricetin
quercetin
chlorogenic acid
composition
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056474 external-priority patent/WO2008115723A1/en
Publication of JP2010522185A publication Critical patent/JP2010522185A/ja
Publication of JP2010522185A5 publication Critical patent/JP2010522185A5/ja
Pending legal-status Critical Current

Links

JP2009554635A 2007-03-19 2008-03-11 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物 Pending JP2010522185A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (2)

Publication Number Publication Date
JP2010522185A JP2010522185A (ja) 2010-07-01
JP2010522185A5 true JP2010522185A5 (https=) 2011-02-03

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554635A Pending JP2010522185A (ja) 2007-03-19 2008-03-11 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物

Country Status (8)

Country Link
US (2) US7943164B2 (https=)
EP (1) EP2129371B1 (https=)
JP (1) JP2010522185A (https=)
CN (1) CN101674821B (https=)
BR (1) BRPI0809047B8 (https=)
CA (1) CA2685031A1 (https=)
MX (1) MX2009009996A (https=)
WO (1) WO2008115723A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
EP2464243A1 (en) * 2009-08-10 2012-06-20 Stokely-Van Camp, Inc. Method for suspending a flavonoid in a beverage
JP5892948B2 (ja) 2010-01-29 2016-03-23 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ カルシウムｈｍｂを含む栄養エマルジョン
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012168108A1 (en) * 2011-06-06 2012-12-13 Unilever Plc An edible composition
CN103620414A (zh) 2011-06-28 2014-03-05 皇家飞利浦有限公司 用于体液检查的部件
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
EP2867663B1 (en) 2012-06-29 2022-12-07 Koninklijke Philips N.V. Processing of bound and unbound magnetic particles
CN104395751B (zh) 2012-06-29 2016-10-19 皇家飞利浦有限公司 含有干扰颗粒的流体的处理
CN104471374B (zh) 2012-07-18 2019-05-21 皇家飞利浦有限公司 对具有目标成分的样本流体进行处理
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
US11071767B2 (en) 2014-04-13 2021-07-27 Marmar Investment Sp. Z O.O. Dietary compositions for reducing blood glucose levels and for weight management
CN106461656B (zh) 2014-06-25 2020-03-24 皇家飞利浦有限公司 用于检测样品中的目标成分的生物传感器
EP3226882A4 (en) * 2014-12-01 2018-07-11 Cape Kingdom Nutraceuticals (Pty) Ltd. Therapeutic compositions
JP6594995B2 (ja) 2015-03-26 2019-10-23 コーニンクレッカ フィリップス エヌ ヴェ バイオセンサカートリッジの製造
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI743349B (zh) 2017-04-03 2021-10-21 大江生醫股份有限公司 包含植物萃取物的組成物及其於促進睪固酮分泌之用途
WO2020247961A1 (en) * 2019-06-07 2020-12-10 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
CA2284290A1 (en) * 1997-03-20 1998-09-24 Samuel Russell Vester Nutritional supplement for cardiovascular health
US7229651B2 (en) * 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
KR20050073611A (ko) * 2002-11-06 2005-07-14 카오카부시키가이샤 혈액 유동성 개선제
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20070092454A1 (en) * 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Similar Documents

Publication Publication Date Title
JP2010522185A5 (https=)
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
RU2014112223A (ru) Способ профилактики и/или лечения инсулинорезистентности
WO2007112069A3 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
EP2330124A3 (en) Hybrid polypeptides with selectable properties
MX2013005110A (es) Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
JP2008534606A5 (https=)
PL2018184T3 (pl) Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
NZ588623A (en) Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
BRPI0809047B8 (pt) composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2008021560A3 (en) Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2008055940A8 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
WO2012068274A8 (en) Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
EP2422807A3 (en) Hybrid polypeptides with selectable properties
WO2011101002A3 (de) Süssstoffzusammensetzungen
JP2015503558A5 (https=)
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2010081720A3 (en) Compositions for the treatment of gastro-esofageal reflux disease (gerd)
WO2010080756A3 (en) Harmine derivatives for reducing body weight
WO2010077101A3 (ko) 신규한 티아졸리딘디온 유도체 및 그의 용도
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
WO2011163319A3 (en) Activation of amp-protein activated kinase by oxaloacetate compounds